Skip to main content
Oxford University Press - PMC COVID-19 Collection logoLink to Oxford University Press - PMC COVID-19 Collection
. 2020 Oct 26:ciaa1637. doi: 10.1093/cid/ciaa1637

Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19

Jakob Malsy 1,#, Luzia Veletzky 1,#, Janna Heide 1,8, Annette Hennigs 1, Ines Gil-Ibanez 1, Alexander Stein 2,3, Marc Lütgehetmann 4,8, Ulrich Rosien 5, Dorothea Jasper 5, Sven Peine 6, Jens Hiller 6, Friedrich Haag 7, Stefan Schmiedel 1, Samuel Huber 1, Sabine Jordan 1, Marylyn M Addo 1,8, Julian Schulze zur Wiesch 1,8,
PMCID: PMC7665388  PMID: 33103195

Abstract

We provide detailed clinical, virological and immunological data of a B-cell depleted patient treated with obinutuzumab for follicular lymphoma with protracted COVID-19 and viremia. A sustained response was achieved after two courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.

Keywords: COVID-19, obinutuzumab, follicular lymphoma, convalescent plasma, remdesivir


Articles from Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America are provided here courtesy of Oxford University Press

RESOURCES